Low-dose Revlimid delayed transfusion dependency and improved treatment response rates in non-transfusion dependent MDS patients. Revlimid reduced the risk of transfusion dependency by 69.8% compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback